Does a Low Histamine Diet Actually Help With PoTS? Here Is What the Evidence Says

The patient community has been talking about this for years. In 2025 a major medical body finally caught up... Here is what we actually know and what we still don't.

Today let’s decode one of the most frequently discussed and least formally evidenced dietary approaches in the PoTS and dysautonomia world. The low histamine diet.

If you spend any time in patient communities online you will have seen it come up. Some people swear by it, whereas others try it and notice nothing. Until recently, the medical establishment had largely stayed quiet on whether it was worth doing at all. That changed in 2025. And the mechanism behind why it might help is actually genuinely interesting.

---

First, what is histamine and why does it matter in PoTS

Histamine is a chemical your body produces naturally that plays a role in immune responses, digestion and neurological signalling. It’s also found in food, particularly fermented, aged, cured, and processed foods, and certain foods trigger your body to release more of it even if they don’t contain much themselves.

In most people, histamine is broken down efficiently by an enzyme called diamine oxidase, or DAO. When DAO isn’t working properly, or when histamine load exceeds the body’s ability to clear it, symptoms start appearing. Flushing, hives, headaches, digestive distress, brain fog, heart racing. Sound familiar?

Here is where it gets relevant to PoTS specifically. Histamine is a potent vasodilator. It causes blood vessels to widen, which in someone with healthy autonomic regulation is manageable. In someone with PoTS, where blood is already pooling in the lower limbs on standing and the autonomic nervous system is already struggling to compensate, adding vasodilation into the mix makes things considerably worse. A 2024 review found that mast cell mediators including histamine directly influence blood vessel tone and permeability, contributing to orthostatic intolerance in PoTS patients. The histamine isn’t just a bystander. It may be actively worsening the core mechanism.

---

A brief word on MCAS

Mast Cell Activation Syndrome (MCAS), is a condition where mast cells, the immune cells that release histamine and other inflammatory mediators, become overactive and degranulate inappropriately. A 2025 study in Frontiers in Neurology found significant overlap between PoTS, hypermobility spectrum disorders (such as EDS) and MCAS, with the three conditions co-occurring at rates much higher than chance (also known as the trifecta). We covered the EDS and PoTS overlap in detail last week, and MCAS sits right in the middle of that picture.

Not every PoTS patient has MCAS, and not every person who benefits from a low histamine diet has MCAS. But for those in whom mast cell activation is part of the picture, the diet makes particular biological sense because it reduces the histamine load the body has to process, giving an already overloaded system a little more breathing room.

---

What the 2025 AGA update actually said

The American Gastroenterological Association published a Clinical Practice Update in 2025 that formally recognised the utility of low histamine diets for patients with MCAS and hypermobile EDS. This is significant because it represents the first time a major gastroenterology body has officially validated an intervention that patients have been self-implementing for years, often without any clinical guidance at all.

Importantly, the AGA’s position is appropriately cautious. They describe the diet as a strategic four to six week elimination trial designed to identify specific triggers, not a permanent lifestyle change. The concern about long-term nutritional restriction is real. A low histamine diet, taken too far and maintained indefinitely, can lead to deficiencies and disordered eating patterns, particularly in a patient population already dealing with significant symptom burden and a complicated relationship with food.

---

What does a low histamine diet actually involve

The diet involves reducing or eliminating foods that are high in histamine or that trigger its release. The main culprits are aged and fermented foods, so alcohol, aged cheeses, cured meats, fermented vegetables, soy sauce, vinegar, and most tinned fish. Leftovers are a particular issue because histamine levels in food increase as it sits, even in the fridge, so fresh is genuinely better rather than just a wellness cliché in this context.

Histamine liberators are a slightly different category. These are foods that prompt your body to release its own histamine even if they don’t contain much themselves. Strawberries, tomatoes, citrus fruits, spinach, and chocolate are commonly listed. Individual sensitivity varies considerably here, which is part of why a trial approach rather than a blanket elimination is the more sensible starting point.

---

What we still don’t know

The honest answer is that the evidence base for low histamine diets in PoTS specifically is extremely thin. Most of what we have is clinical observation, patient reported outcomes, and mechanistic reasoning rather than randomised controlled trials. The AGA guidance is based on expert consensus and clinical experience rather than large-scale trial data. The difficulty of blinding someone to a dietary intervention makes proper randomised trials hard to design and harder to fund.

We also don’t have a reliable way to test whether someone’s PoTS is being meaningfully driven by histamine load. DAO enzyme testing exists but is not standardised and not widely available on the NHS. Urinary histamine metabolites can be measured but the diagnostic window is narrow and results are inconsistent. Most people end up trialling the diet empirically, which is arguably a reasonable approach given the low risk, but it does mean we can’t predict who will benefit.

---

The take home message

If you have PoTS and notice that your symptoms are worse after alcohol, fermented foods, leftovers, or the foods listed above, a four to six week low histamine elimination trial is a low-risk, evidence-adjacent thing to try with your clinician’s knowledge. It is not a cure and it is not for everyone. But the mechanism is plausible, the 2025 AGA guidance gives it more clinical credibility than it had before, and for a subset of people, particularly those with MCAS overlap, it may make a meaningful difference to symptom load.

Work with a dietitian if you can, particularly one who understands PoTS and MCAS. Going too restrictive for too long creates its own problems, and the goal is information, not indefinite elimination.

---

References

Theoharides TC, Twahir A, Kempuraj D. Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation. Annals of Allergy, Asthma and Immunology. 2024. https://doi.org/10.1016/j.anai.2023.10.032

Afrin LB, et al. Mast cell activation syndrome: current understanding and research needs. Journal of Allergy and Clinical Immunology. 2025. https://www.jacionline.org/article/S0091-6749(24)00569-4/fulltext

Yao L, et al. Association of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patients. Frontiers in Neurology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12063504/

Lam C, et al. AGA Clinical Practice Update on diagnosis and management of immune and mast cell mediated GI conditions. Gastroenterology. 2025.

Hamilton MJ, et al. Mast cell activation disorder and postural orthostatic tachycardia syndrome. Journal of the American Heart Association. 2021. https://www.ahajournals.org/doi/10.1161/JAHA.121.021002

---